| Bioactivity | BGG463 (K03859) is an orally active type II CDK2 inhibitor[1]. | ||||||||||||
| Invitro | BGG463 potently inhibits T315I BCR–ABL autophosphorylation and shows good oral efficacy in mouse models of CML[2]. | ||||||||||||
| Name | BGG463 | ||||||||||||
| CAS | 890129-26-7 | ||||||||||||
| Formula | C30H29F3N6O3 | ||||||||||||
| Molar Mass | 578.58 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Alexander LT, et al. Type II Inhibitors Targeting CDK2. ACS Chem Biol. 2015 Sep 18;10(9):2116-25. [2]. Jones K, et al. Cancer Drug Discovery 2010: from molecules to medicine. Expert Rev Clin Pharmacol. 2010 Sep;3(5):613-5. |